Since then, an expanded access program has shown a favorable side-effect profile and clinical efficacy of dNMP and deoxynucleoside therapies in patients with TK2 deficiency, some of them included in this study. The gene discussed is TK2; the disease is hyperinsulinemic hypoglycemia, familial, 4.